Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 7/20 | 0.51 |
| ▸ | CA2 | P00918 | 7/20 | 0.51 |
| ▸ | CA12 | O43570 | 6/20 | 0.51 |
| ▸ | CA9 | Q16790 | 6/20 | 0.51 |
| ▸ | CA4 | P22748 | 5/20 | 0.51 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.41 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.41 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19977289 | 0.80 | CA1 (0.59) | CA1CA2CA12CA9CA4 | |
| SCHEMBL16038237 | 0.80 | CA1 (0.59) | CA1CA2CA12CA9CA4 | |
| SCHEMBL21587286 | 0.77 | CA1 (0.62) | CA1CA2CA12CA9CA4 | |
| SCHEMBL16036503 | 0.76 | RPS6KA1 (0.37) | CA1CA2CA12CA9CA4 | |
| SCHEMBL16036504 | 0.76 | RPS6KA1 (0.37) | CA1CA2CA12CA9CA4 | |
| SCHEMBL19582180 | 0.76 | CA2 (0.58) | CA1CA2CA12CA9CA4 | |
| SCHEMBL18360534 | 0.76 | CA1 (0.54) | CA1CA2CA12CA9CA4 | |
| SCHEMBL22031678 | 0.76 | CA1 (0.54) | CA1CA2CA12CA9CA4 | |
| SCHEMBL19582181 | 0.76 | CA2 (0.58) | CA1CA2CA12CA9CA4 | |
| SCHEMBL29091146 | 0.76 | CA1 (0.58) | CA1CA2CA12CA9CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10851119-B2 | Boron-containing diacylhydrazines | INTREXON CORPORATION (US) | 2020-12-01 | — | — | US | disclosed |
| US-20200157122-A1 | BORON-CONTAINING DIACYLHYDRAZINES | INTREXON CORP (US) | 2020-05-21 | — | — | US | disclosed |
| US-9512148-B2 | Boron-containing diacylhydrazines | INTREXON CORPORATION (US) | 2016-12-06 | — | — | US | disclosed |
| US-20150322092-A1 | Boron-Containing Diacylhydrazines | INTREXON CORPORATION (US) | 2015-11-12 | — | — | US | disclosed |
| US-9127024-B2 | Boron-containing diacylhydrazines | INTREXON CORPORATION (US) | 2015-09-08 | — | — | US | disclosed |
| US-20140274954-A1 | Boron-Containing Diacylhydrazines | INTREXON CORPORATION | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322092-A1 | Boron-Containing Diacylhydrazines | CD22, BRDT, BCR | CA1 2249/4885CA2 1770/4885CA12 300/4885 |
| US-10851119-B2 | Boron-containing diacylhydrazines | CD22, BRDT, BCR | CA1 2249/4885CA2 1770/4885CA12 300/4885 |
| US-20200157122-A1 | BORON-CONTAINING DIACYLHYDRAZINES | CD22, BRDT, BCR | CA1 2249/4885CA2 1770/4885CA12 300/4885 |
| US-20140274954-A1 | Boron-Containing Diacylhydrazines | CD22, BRDT, BCR | CA1 2249/4885CA2 1770/4885CA12 300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.